Vortioxetine for the treatment of post-COVID-19 condition: a randomized controlled trial
Description
Hitherto no therapeutic has received regulatory approval for the treatment of Post-COVID-19 Condition (PCC). Cognitive deficits, mood symptoms, and significant reduction in health-related quality of life (HRQoL) are highly replicated and debilitating
